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Amphiphilic poly(ethylene oxide)–poly(propylene oxide) (PEO–PPO)-based copolymers are 
thermoresponsive materials having aggregation properties in aqueous medium. As hydrosolubilizers of 
poorly water-soluble drugs and improved stability of sensitive agents, these materials have been 
investigated for improvement in solubility, stability, release and bioavailability of drugs. The goal of the 
present review is to summarize the properties of PEO–PPO based copolymers and highlight the works 
that have been carried out on these materials for transdermal drug delivery.  
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INTRODUCTION 
 
Advances in pharmaceutical technology led 
to the design of technologically optimal 
vehicles for the administration of drugs, thus 
allowing improvement in the properties of the 
preparations as well as maximization of their 
stability, bioavailability and biocompatibility. 
However, a persisting drawback is low 
solubility in physiological aqueous 
environment of about 50 % of approved 
active molecules, resulting in poor 
bioavailability [1]. Limited solubility also 
constitutes a hurdle in the development of 
topical formulations, and improved solubility 
usually correlates well with higher 
bioavailability [1-3].  
 
Inclusion of hydrophobic molecules within 
polymeric micelles is a solution approach to 
enhanced drug solubilization, stability and 
bioavailability. Polymeric micelles are 
nanoscopic (> 100 nm) structures formed by 
amphiphilic block copolymers composed of 
hydrophilic and hydrophobic chains that self-
assemble in water, above a certain 
concentration named the critical micelle 
concentration (CMC) [1,4]. Micelles comprise 
of an inner and outer domain referred to as 
core and shell, respectively. Due to the 
hydrophobic nature of the core, these entities 
particularly suitable for the solubilization of 
water insoluble molecules, protection of 
unstable agents from chemical degradation 
and metabolism by biological agents, and 
sustained release in different formulations 
[1,5]. Among the polymers displaying micelle-
formation ability, the most broadly 
investigated amphiphilic materials are 
derivatives of PEO–PPO block copolymers 
[1,6,7] which form swellable hydrogels. 
Swollen hydrogels, which give more emollient 
effect than conventional ointments due to 
their high water content, have been preferred 
for topical-transdermal drug delivery in recent 
years.  
 
Transdermal delivery of drugs using PEO–
PPO-based polymeric micelles has been 
investigated for the delivery of mostly anti-
inflammatory drugs [8-19], analgesic [20], 
local anesthetic [21], other drugs [19,22-24] 
and proteins [25,26]. In this review, we 
present an overview of the properties of 
PEO–PPO based copolymers and their 
applications in transdermal drug delivery.  
 
PROPERTIES OF PEO–PPO BASED 
COPOLYMERS 
 
This group of copolymers consists of 
ethylene oxide (EO) and propylene oxide 
(PO) blocks arranged in a triblock structure 
EOx-POy-EOx. Their chemical formula is 
HO[CH2-CH2O]x [CH(CH3)-CH2O]y[CH2-
CH2O]xOH, where y is greater than 14. 
Registered trademarks of these copolymers 
(e.g., Pluronic® Synperonic® or Tetronic®) 
cover a large range of liquids, pastes and 
solids. Two families are available: (1) the 
linear and bifunctional PEO–PPO–PEO 
triblocks or poloxamers (Pluronic and 
Synperonic) and (2) the branched 4-arm 
counterparts named poloxamine (Tetronic) 
[1].  
 
They are synthesized by sequential 
polymerisation of PO and EO monomers in 
the presence of sodium hydroxide or 
potassium hydroxide [27,28]. The initial stage 
of the synthesis includes growth of the PO 
block followed by the growth of EO chains at 
both ends of the PO block. Anionic 
polymerization usually produces polymers 
with a low polydispersity index (Mn/Mw). 
However, the commercially available Pluronic 
preparations may contain admixtures of the 
PO homopolymer as well as di- and triblock 
copolymers, exhibiting lower degrees of 
polymerization than expected [29]. These 
copolymers are available in a wide range of 
molecular weights and EO/PO ratios [1]. 
They have amphiphilic properties 
characterised by their HLB values 
(hydrophilic-lipophilic balance), in which the 
number of hydrophilic EO (x) and 
hydrophobic PO (y) units can be altered to 
vary the size, hydrophilicity and lipophilicity 
easily [27,29].   
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The most extensive work was performed on 
the poloxamer (Pluronic) group. The 
poloxamers consist of more than 30 different 
non-ionic surface-active agents. The 
poloxamer series covers a range of liquids, 
pastes, and solids, with molecular weights 
and EO-PO weight ratios varying from 1100 
to 14,000 and 1:9 to 8:2, respectively. 
Concentrated aqueous solutions of 
poloxamer form thermoreversible gels [30].  
 
A defining property of poloxamer is the ability 
of the individual block copolymer molecules, 
termed ‘unimers’, to self-assemble into 
micelles in aqueous solutions. These 
‘unimers’ form a molecular dispersion in 
water at block copolymer concentrations 
below the critical micelle concentration 
(CMC). At concentrations of the block 
copolymer above the CMC, the unimer 
molecules aggregate, forming micelles 
through a process called ‘micellization’. The 
driving force for the micellization is the 
hydrophobic interactions of the PO blocks. 
The number of block copolymer unimers 
forming one micelle is referred to as the 
‘aggregation number’. Usually this number 
ranges from several to over a hundred. The 
process of transfer of water-insoluble 
compounds into the PO core of the micellar 
solution is referred to as ‘solubilization’ [29]. 
The gelation mechanism of poloxamer 
solutions has been investigated extensively, 
but is still being debated. Ultrasonic velocity, 
light-scattering and small-angle neutron 
scattering measurements of aqueous 
poloxamer solutions have clearly indicated a 
micellar mode of association [30,31-36]. 
Micelle formation occurs at the critical 
micellization temperature as a result of PPO 
block dehydration [30,33,37]. With increasing 
temperature, micellization becomes more 
important, and at a definite point, micelles 
come into contact and no longer move. Thus, 
packing of micelles and micelle 
entanglements may be possible mechanisms 
of poloxamer solution gelation with increased 
of temperature [30,38]. In addition, the 
formation of highly ordered structures, such 
as cubic crystalline phase, has been 
proposed as the driving force for gel 
formation [30,34–36,39], but this hypothesis 
has been questioned by some of the 
researchers [30]. In order to attain relatively 
stable gels, these applications require 
polymer concentrations of usually around 15 
wt% [1,40-43].  
 
Poloxamers (Pluronics) are nonionic 
surfactants possessing excellent wetting, 
antifoaming and solubilizing properties. 
Though their potential drawbacks include 
weak mechanical strength and rapid erosion 
(i.e., dissolution from the surface) [44,45], 
poloxamer gels have been shown to provoke 
neither skin irritation nor sensitivity, thus 
confirming its good tolerability and useful in 
topical formulations [1,8,44,46]. Among 
these, Poloxamer 407, also known as Lutrol 
or Pluronic F127, is an ABA-type triblock 
copolymer consisting of PEO units (A = 70%) 
and PPO units (B = 30%), which is 
transformed from a low-viscosity solution to a 
semisolid gel upon heating to body 
temperature at concentrations of > 20 % 
[47,48], have become the subject of growing 
interest for use in the formulation of dosage 
forms owing to their low toxicity and ability to 
form a clear solution or gel in aqueous media 
[8,49]. To increase their applicability, 
poloxamers can be physically or chemically 
modified by different polymenrs [47,50,51].  
 
PEO–PPO BASED COPOLYMERS IN 
TRANSDERMAL DRUG DELIVERY 
 
Studies on PEO–PPO-based polymeric 
micelles for transdermal drug delivery have 
been widely carried out with Poloxamer 407 
(Pluronic F127) and these studies mostly 
focused on small drug molecules in order of 
anti-inflammatory [8-19], analgesic [20], local 
anesthetic [21] and cardiac effectiveness 
[19,22-24] and rarely focused on big 
molecules such as arginine vasopressin 
(AVP) and insulin [25,26].  
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Delivery of small molecules 
 
An interesting study based on a dual purpose 
gel was designed by Cafaggi et al to increase 
the aqueous solubility of tolfenamic acid, an 
anti-inflammatory drug, at least 2000-fold at 
25 oC through the use of Poloxamer 407 and 
evaluated a gel based on this poloxamer for 
the topical or transdermal administration of 
the drug [9]. The sustained release of 
tolfenamic acid towards the receptor phase 
constituted by isopropyl myristate was 
accompanied, in its early stage, by the 
concomitant release of ethanol and 
tetrahydrofurfuryl alcohol used as cosolvents 
to obtain a drug loading of 0.6% (w/w). The 
poloxamer micellar phase was directly 
involved in the late stage of drug release, 
thus indicating that a strong interaction 
occurred in the gel between the poloxamer 
and tolfenamic acid. The results indicate the 
possibility of both systemic and topical 
administration of tolfenamic acid by means of 
aqueous solutions or gels containing 
Poloxamer 407 in an adequate concentration. 
The solubilization process was spontaneous 
and exothermic, as indicated by thermo-
dynamic parameters [8].  
 
The solubility of naproxen, another anti-
inflammatory agent, at pH 2 was significantly 
increased as a linear function of Poloxamer 
407 concentration and the micellar 
solubilization was spontaneous and 
exothermic. The release of naproxen from 
Poloxamer 407 gel across the membrane into 
isopropyl myristate was dependent on 
medium pH and was significantly sustained at 
pH 2, with an inversely proportional to the 
surfactant concentration [10].  
 
Various hydrogel formulations loaded with 
poorly water-soluble piroxicam for 
transdermal delivery has been investigated 
by some researchers [11,12,15]. The 
pharmacokinetics and anti-inflammatory 
activity of piroxicam from Poloxamer 407 gel 
were determined to investigate percutaneous 
absorption of piroxicam from poloxamer gels 
in rats; Poloxamer 407 gel containing 1 % 
piroxicam showed significant inhibition of 
carragenin-induced rat foot swelling (%) with 
a linear relationship of piroxicam dose within 
~0.4 – 3.2 mg/kg when compared to the 
control group (Figure 1).  
 
 
Figure 1: Dose response of piroxicam after paw 
injection into the sole of rat carrageenan-induced 
edema model;  = % swelling,  = % inhibition 
[11].  
 
Piroxicam diffusion in Poloxamer 407 
hydrogel was evaluated with a new technique 
(UV imaging) and monitored by measuring 
the absorbance of light passing through the 
diffusion cell at 26 oC, thus providing real-
time concentration maps (7 x 3 mm imaging 
area) within the gel as a function of time. This 
study indicates that UV imaging has great 
potential for measuring drug diffusion in and 
release from gel matrices. Compared to the 
currently used conventional techniques, this 
technology has several advantages including 
high information content, non-intrusive 
measurements without the need for labeling, 
flexibility with respect to experimental design 
and simplicity of operation [12]. 
 
The percutaneous absorption of a new 
synthetic capsaicin analog, a potent anti-
inflammatory analgesic drug, from a 
Poloxamer 407-based formulation was 
studied by Lee et al [18]. The results showed 
that the flux of poloxamer-based gels 
increased linearly as drug concentration 
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increased and at 32 °C was higher for free 
base form of drug than that of its salt form. 
There was a variation in percutaneous 
absorption of the drug, depending on the 
species used and was highest in hairless 
mice but lowest in hamsters, and there was 
no skin toxicity. The poloxamer-based 
formulation appears useful in the systemic 
delivery of capsaicin as topical or transdermal 
patch formulations [18].  
 
The feasibility of PEO–PPO–PEO copolymer 
with average molecular weight of 8400 gel as 
a release vehicle for percutaneous 
administration of analgesic fentanyl was 
investigated by in vitro and in vivo studies. At 
a concentration of 46% at 37 oC, PEO–PPO–
PEO copolymers formed a gel and showed a 
pseudo-zero-order sustained-release profile 
as presented in Figure 2. Assessment of the 
effect of the copolymer on nude mouse skin 
showed a decrease in the apparent 
permeability coefficient and pharmacokinetics 
of the fentanyl patch was shown to be in 
steady state within 24 h, and this was 
maintained for at least 72 h. Thus, it appears 
that fentanyl preparations based on PEO–
PPO–PEO copolymer gel might be practical 
for percutaneous delivery [20].  
 
 
Figure 2: Effect of PEO–PPO–PEO copolymer 
concentration on fentanyl release from a cellulose 
membrane (: H2O, : 46 %, ▼: 20%, : 10 %, 
: 1 %, : 0.1 %, : 0.01 %, : 0.001 %;  each 
value represents the mean ± S.D. of n53)  [20]  
 
The percutaneous delivery of pranoprofen 
from Poloxamer 407 and hydroxypropyl 
methylcellulose (HPMC) gel mixture was 
investigated and it was found that the rate of 
drug permeation increased significantly with 
increasing drug concentration in the gels, up 
to 0.16 %, and increased with increasing 
temperature, with an activation energy (Ea) of 
8.88 kcal/mol which highlighted the feasibility 
of a topical gel formulation of pranoprofen 
[13]. To develop lidocaine gels of enhanced 
local anesthetic effects, HPMC-Poloxamer 
407 gels were formulated; as drug 
concentration in the gels increased up to 3 %, 
drug permeation rate linearly increased, 
reaching a plateau. Also, as the temperature 
of the surrounding solution increased, the 
permeation of drug increased as well [21].  
 
Suedee et al [23] aimed to develop a 
transdermal patch for selective controlled 
delivery of the active S enantiomer of racemic 
propranolol, and to evaluate its performance 
in vivo using Wistar rats. A molecularly 
imprinted polymer (MIP) thin-layer 
composited cellulose membrane having 
selectivity for S-propranolol was employed as 
enantioselective-controlled release system. 
The effect of gel reservoir (poloxamer and 
chitosan) on enantioselective drug delivery 
was investigated. The chitosan gel allowed 
excellent selectivity for delivery of the S-
propranolol enantiomer, whilst the more 
rheologically structured poloxamer gel 
formulation provided no selective release of 
S-propranolol. The chitosan gel exhibited 
high flux and had the ability to 
enantioselective deliver S-propranolol across 
excised rat skin. The results demonstrated 
that transdermal patch based on the MIP 
composite membrane-controlled release 
system may have potential in 
enantioselective-controlled delivery of S-
isomer of racemic propranolol [23]. 
 
Transdermal delivery of timolol (TM) from a 
Poloxamer 407 gel reservoir system has 
been investigated; it was found that both the 
gel concentration and the artificial membrane 
can be used as “tools” to regulate TM 
delivery from gel reservoir. At low 
concentrations of Poloxamer 407 and high 
pore  size of the membranes (Polyflux®, 
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PES-30), the stratum corneum mainly 
controls TM delivery. At high Poloxamer 407 
concentrations and low pore size of 
membranes (NF-PES-10), the contribution of 
the device (gel+artificial membrane) on the 
delivery of TM was found to be significant 
[24].  
 
Effect of additives on the delivery of small 
molecules from poloxamers  
 
Among the enhancers, non-ionic surfactants 
have attracted attention in drug delivery from 
poloxamers-based systems. The enhancing 
effect of polyoxyethylene-2-oleyl ether, a non-
ionic surfactant, on percutaneous absorption 
of piroxicam from Poloxamer 407 gel was 
evaluated in rats by Shin et al [11]. The 
piroxicam gel containing polyoxyethylene-2-
oleyl ether increased the relative 
bioavailability ~1.8-fold compared with the gel 
without enhancer. Percutaneous 
administration of piroxicam gel containing 
polyoxyethylene-2-oleyl ether to rats showed 
relatively constant, sustained blood 
concentration with minimal fluctuation [11].  
 
 
Figure 3: Effect of non-ionic surfactants in the 
poloxamer gel containing 1% piroxicam on drug 
permeation through excised rat skin ( = control, 
 = polyoxyethylene-23-laurylether, ▼= polyoxy-
ethylene-2-oleylether,  = polyoxyethyl-ene-2-
stearyl ether)  [15].  
 
The enhancing effect of non-ionic surfactants 
on the permeation of piroxicam from the 
poloxamer gels was evaluated in another 
study by Shin et al [15]. The effectiveness of 
penetration enhancers, measured by ratio of 
piroxicam flux in the presence or absence of 
enhancers (enhancement factor) indicate that 
polyoxyethylene-2-oleyl ether showed the 
highest enhancing effects (Figure 3) with an 
enhancement factor of 2.84 among the 
studied surfactants. Thermal analysis 
revealed that various surfactants have 
different fluidizing effects on stratum 
corneum, and skin pretreated with the 
Poloxamer 407 gels containing various 
surfactants showed a loosely layered stratum 
corneum and wide intercellular space that 
elucidated the mechanisms of the action of 
enhancers [15].  
 
The effect of four terpene enhancers, 
enhancer lipophilicity and ethanol 
concentration using hydroxypropyl cellulose 
(HPC) and two Poloxamer 407 gel 
formulations on the in vitro percutaneous 
permeation of ketoprofen from hairless 
mouse skin were evaluated by El-Kattan et al 
[17]. The highest increase in ketoprofen 
permeation was observed using limonene 
followed by nerolidol, fenchone and thymol 
for all formulations. Moreover, ethanol had a 
synergistic effect on the enhancing activity of 
the terpenes [17]. In another study, effect of 
two terpenes (d-limonene and 1-menthol) 
were evaluated for 20 % ibuprofen in 30 % 
Poloxamer 407 formulation. Avoiding gel 
formation and in order to assess their drug 
diffusion/penetration (permeation) into the 
skin, it was revealed that the superior 
enhanced permeationof terpenes, especially 
d-limonene, was dependent on ibuprofen in 
fluid preparations which may be useful as a 
topical preparation of ibuprofen [14]. 
 
The penetration of sodium naproxen, 
formulated in Poloxamer 407 gels containing 
Azone and Transcutol as penetration 
enhancers, was studied through human skin 
in vivo. It was found that the combination of 
Azone and Transcutol in Pluronic F127 gels 
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enhanced sodium naproxen penetration, with 
enhancement ratios of up to two-fold 
compared with the formulation containing 
only Transcutol. This was confirmed by 
transepidermal water loss and attattentuated 
total reflectance FTIR spectroscopy analyses 
by Escobar-Chavez et al [16].  
 
The effect of different types of enhancers was 
evaluated on the permeation rate of lidocain 
through skin from HPMC-Poloxamer 407 
gels. Among the enhancers, such as glycols, 
non-ionic surfactants and bile salts, 
diethylene glycol showed the greatest 
enhancing effect on drug permeation through 
skin, and in the area under the efficacy curve 
(AUEC) of the rat-tail flick tests, lidocaine gel 
containing diethylene glycol showed about 
3.89-fold increase in analgesic activity 
compared with control [21].  
 
The effect of dimethyl sulphoxide (DMSO) on 
the micellization, gelation and dissolution 
properties of aqueous poloxamer solutions, 
clearly showed that DMSO induces 
reductions in critical micellization and gelation 
temperatures of poloxamer systems analyzed 
by differential scanning calorimetry and tube 
inversion experiments. In addition, high 
resolution solid state 1H magic angle 
spinning nuclear magnetic resonance 
analyses provided indications of the specific 
chemical groups in the poloxamer affected by 
DMSO, and the molecular mechanism 
involved. The presence of DMSO accelerated 
dissolution of the pure gel in water and the 
release of a hydrophobic drug (flufenamic 
acid) from poloxamer gel, while it reduced the 
release of a hydrophilic drug (metoprolol 
tartrate) [19].  
 
The crystallization of drug in a matrix may 
significantly affect the efficacy and quality of 
a transdermal drug delivery system. 
Therefore, control of drug crystallization is of 
particular interest in the development of 
efficient transdermal delivery systems. From 
this point of view, the crystallization inhibition 
effect of poloxamer was investigated as an 
additive and it was found that poloxamer 
significantly inhibited the crystallization of 
ketoprofen in a polyisobutylene adhesive 
matrix, in a study by Kim and Choi [52]. 
 
The salts commonly included in the 
formulation of Poloxamer 407 gels can 
dramatically change the release rate of a 
drug. In a salt effect study, the release rate 
and diffusion coefficient of propranolol, a 
model drug, were significantly reduced when 
NaCl, Na2SO4, NaH2PO4, MgSO4 and CaCl2 
were added to the gels of 21 % Poloxamer 
407 in an aqueous medium at 37 °C through 
a cellulose membrane, as presented in 
Figure 4. The magnitude of the effect on 
release rate depends on the nature and 
concentration of the salt. Since propranolol is 
expected to be located outside the micelles in 
the gel, these salt effects have been 
attributed to increase in the microviscosity of 
the aqueous regions of the gel, rather than to 
a change in micellization behavior. It is 
analogous to the change in the aggregation 
and phase behavior of aqueous solutions of 




Figure 4: Effects of 0.1 molal concentrations of 
various salts on release rate of propranolol from a 
21% Poloxamer 407 gel at 37°C. (: no salt, : 
CaCl2 , : NaCl, : MgSO4, : NaH2PO4, : 
Na2SO4 ;  Linear regression lines are fitted to the 
data) [22]. 
 
The influence of the addition of lecithin, a 
permeation enhancer, on the rheological and 
in vitro permeation properties of Poloxamer 
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407 gels was investigated by Vito´ria et al 
[53].  
 
Light microscopy and rheological parameters 
were used to characterize the microscopic 
structure of the formulation that showed non-
Newtonian behaviour, i.e., pseudoplastic flow 
with a yield value (Figure 5). The results 
revealed that increased concentration of 
lecithin increased the thixotropy, yield value, 
apparent viscosity, and gelation temperature 
of the gels. Light microscopy showed the 
formation of micellar structures following the 
addition of lecithin, which may account for 
changes in rheological properties. In vitro 
permeation of a model drug, triamcinolone 
acetonide, was decreased when lecithin 
concentration was increased. The presence 
of lecithin in the poloxamer gel improved the 
characteristics for topical drug delivery [53]. 
 
 
Figure 5: Rheograms of Poloxamer 407 gel (25% 
w/v) at 25°C as a function of lecithin concentration: 
(a) 0%; (b) 1%; (c) 2%; (d) 4%; and (e) 8% w/v 
[53]. 
 
Non-ionic surfactants belonging to the class 
of poloxamer (Pluronic) and sucrose esters 
were used both as components of niosomal 
systems or in the form of sub-micellar 
solutions. The niosomes obtained were 
characterized by their entrapment efficiency, 
size and morphology. The enhancing effect of 
niosomes on the ex vivo percutaneous 
penetration of a model drug was investigated 
using a Franz-type diffusion chamber and 
compared to that obtained by using sub-
micellar solution of surfactant or achieving 
pretreatment of the skin with surfactants’ sub-
micellar solution or empty niosomes. The 
results suggest that the surfactants used in 
this study could be considered as 
percutaneous permeation enhancers only 
when they are in the form of drug-loaded 
vesicular systems. No percutaneous 
promotion was achieved by using sub-
micellar solution containing free sulfadiazine 
sodium salt or performing pretreatment with 
empty niosomes or sub-micellar solutions of 
the surfactant. Only niosomes were found in 
their experiments to be effective as 
transdermal drug delivery systems by 
Muzzalupo et al [54]. 
 
Delivery of big molecules 
 
Nair and Panchagnula [25] studied the 
pharmacokinetic and pharmacodynamic 
activities of arginine vasopressin (AVP), a 
nanopeptide with antidiuretic activity, on 
being delivered by transdermal iontophoresis. 
Poloxamer 407 was used to form stable gels 
that did not reduce the release of AVP. The 
release rate from the gel followed Higuchi 
kinetics indicating that the dominant 
mechanism of release is diffusion [25]. A 
matrix gel formulation would be more 
adaptable from an iontophoretic device point 
of view. Poloxamer 407 could be used to 
formulate stable gels of a peptide 
vasopressin without inhibiting its release from 
the matrix. The release of peptide from the 
gel followed Higuchi kinetics indicating that 
the release was predominantly diffusion-
controlled. The correlation between blood 
levels and pharmacodynamic activity was 
only qualitative for vasopressin. Iontophoresis 
alone and in combination with chemical 
enhancers which were used to augment the 
transdermal permeation of AVP. The results 
of both pharmacokinetic and pharmaco-
dynamic studies emphasize the dimension of 
‘rapid onset’ achieved by iontophoresis. 
Correlation between pharmacokinetic and 
pharmacodynamic activities was only 
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qualitative. Histopathological studies revealed 
that skin toxicity, caused by either 
iontophoresis or chemical enhancers when 
used alone, could be reduced by using a 
combination of both techniques in tandem 
[25]. 
 
Insulin has been used as a model peptide for 
transdermal delivery of large peptides in the 
molecular weight range of 3 – 7 kDa. A gel 
formulation of insulin formulated using 
Poloxamer 407 was evaluated by Pillai and 
Panchagnula [26] in ex vivo and in vivo skin 
permeation studies in rat with chemical 
enhancer and/or iontophoresis. The authors 
observed that the poloxamer gel was 
physically and chemically stable during the 
storage period. In ex vivo studies, both 
linoleic acid and menthone in combination 
with iontophoresis showed synergistic 
enhancement of insulin permeation. Plasma 
insulin concentration (PIC) was highest with 
linoleic acid pre-treatment, in agreement with 
ex vivo permeation studies, but reduction in 
plasma glucose levels (PGL) was 
comparable to iontophoresis. Menthone pre-
treatment resulted in rapid attainment of peak 
PIC, but reduction in PGL was less than in 
other treatment groups. They found that there 
was no direct relationship between PIC and 
PGL, and this was attributed to the fact that 
the action of insulin is mediated by a cascade 
of cellular mechanisms, before a reduction in 
PGL is observed. However, iontophoresis, 
either alone or in combination with linoleic 
acid, produced a reduction in PGL to the 
extent of 36 – 40 %. A combination of 
chemical enhancers and iontophoresis 
caused greater skin irritation than when either 
of them was used alone [26]. 
 
The effect of Poloxamer 188 on 
electroporation of artificial lipid membranes 
made of azolectin was investigated by 
Sharma et al [55]. Two different experimental 
protocols were used in the study - charge 
pulse and voltage clamp. Several parameters 
characterizing the electroporation process 
were measured and compared with control 
membranes and membranes treated with 1.0 
mM Poloxamer 188. It was found that for both 
charge pulse and voltage clamp experiments, 
Poloxamer 188-treated membranes exhibited 
a statistically higher threshold voltage (p = 
0.1 and p = 0.06, respectively), and longer 
latency time (p = 0.04 and p = 0.05, 
respectively). These findings suggest that 
Poloxamer 188 adsorbs into the lipid bilayers, 
thereby decreasing their susceptibility to 
electroporation [55]. 
 
A Poloxamer 407 gel containing dimethyl 
isosorbide, isopropyl alcohol, propylene 
glycol dicaprylocaprate and water has been 
suggested for permeation enhancement of 5-
aminolevulinic acid (ALA) across isolated 
human stratum corneum, in a study by 
Grüning and Müller-Goymann [56]. A further 
contribution was the development of a 
pseudo ternary phase diagram with water, a 
fixed combination of 1:1 of isopropyl alcohol 
and dimethyl isosorbide, and a fixed ratio of 
4:1 Poloxamer 407 to propylene glycol 
dicaprylocaprate. The systems were 
categorized according to their consistencies 
and ringing gel characteristics with special 
emphasis on appropriate formulations for 
dermal application. Polarizing microscopy 
enabled a clear differentiation between 
isotropic and anisotropic systems. Wide 
angle X-ray diffraction analyses confirmed 
that anisotropy was due to crystalline 
Poloxamer 407. Furthermore both methods 
showed that isopropyl alcohol/dimethyl 
isosorbide was an inferior solvent mixture for 




One of the developments in technologically 
optimal vehicles for the administration of 
drugs is polymeric micelles which improves 
solubility, stability, bioavailability and 
biocompatibility depending on the properties 
of active substance. Long-term investigations 
indicate that PEO–PPO-based copolymers 
that display micelle-formation ability provide 
improvement in solubility and delivery of 
water insoluble molecules via transdermal 
way, and they have the advantages of 
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protecting drug from first-pass metabolism 
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